

Australians with  
advanced or  
incurable cancers...



Meet accelerated  
access to precision  
oncology

Omico, a pioneering, national, not for profit organisation, is uniting Australia's world-class cancer institutes, researchers, industry partners and government like never before, harnessing the combined expertise and resources across the country.

**We are changing the way we fight cancer by accelerating access to precision oncology, improving outcomes for Australians.**

Cancer  
meets its match



Omico.

# Precision oncology has revolutionised our ability to fight cancer more than ever before

**Precision oncology** uses genomic profiling (screening) to detect unique genetic variations in cancer patients' tumours, enabling us to predict, prevent, diagnose and treat cancer at an individual level.

At Omico, we are providing Australian patients with advanced or incurable cancer accelerated access to free comprehensive genomic profiling, enabling us to potentially **match them to clinical trials with new targeted therapies** faster for improved outcomes.

**Omico's research\* has found that:**

1 in 3



(38%) patients screened received guidance on new targeted treatments<sup>1</sup>

~50%



Improved survival rate with matched therapy<sup>1</sup>

\*Molecular Screening and Therapeutics (MoST) Study

We're ramping up our fight against cancer. **Through our landmark initiative, ProSPeCT, we provide:**

- 23,000 patients across the nation access to cutting-edge genomic profiling
- Including rural, regional, and Aboriginal and Torres Strait Islander communities
- New pathways for difficult-to-treat cancers
- Treatment recommendations from the team of experts in our Molecular Oncology Board
- Improved patient outcomes with less side effects

# PrOSPeCT is the largest cancer genomics initiative in Australia

The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) is a world-leading initiative, which will enable Australia to tap into the global cancer research market – currently valued at more than A\$130B.

PrOSPeCT is **enabled by public-private funding and partnerships**, totalling over \$185M, including \$61.2 million in grant funding from the Australian Government as part of the Modern Manufacturing Strategy and \$25M from the NSW Government.

Over 27 months, PrOSPeCT's Cancer Screening Program (CaSP) will provide free genomic profiling to 23,000 Australians with advanced or incurable cancers and identify potential matches for patients to clinical trials with new targeted therapies.

**PrOSPeCT is anticipated to drive growth for the Australian research sector by:**

## Expanding



Australia's research capabilities and capacity

## Positioning



Australia as a premier hub for cancer research

## \$525M

New direct investment in locally based clinical trials



## >650

Jobs created in genomics, clinical trials and diagnostics in two years



## \$135M

Savings from avoided health interventions (medicines, tests, hospitals)



## Advancing

drug development and cancer research through collection of real-world data



# Help provide accelerated access to free genomic testing for patients with cancer

## What you can do for your constituents:

For people with advanced  
or incurable cancer:

**Recommend they ask  
their cancer doctor about  
free genomic testing  
through Omico now**

If they would like  
more information:



**Recommend they  
visit [omico.com.au](https://www.omico.com.au)  
to learn more**

## About Omico

Omico is a collaborative, national, not for profit organisation that is changing the way we fight cancer by accelerating access to precision oncology, improving outcomes for Australians.

PrOSPeCT foundation partners are: Roche Australia, NCI (National Computational Infrastructure, Australian National University) and the Children's Cancer Institute.

Other industry and public sector partners include: Bayer Australia, Bioplatforms Australia, Elevation Oncology, George Clinical, Illumina, Microba, Peter MacCallum Cancer Centre, PRAXIS Australia, Quantum, Sonic Healthcare, Southern Star Research, Syntro Health.

For a full list of partners, supporters and cancer treatment and research centres in the Omico network, visit: <https://www.omico.com.au/about-us/our-network-partners/>

**Reference: 1.** Omico Data on File.

T. 1800 954 350  
E. [contact@omico.org.au](mailto:contact@omico.org.au)

© Copyright 2023. Australian Genomic Cancer Medicine Centre Ltd,  
trading as Omico, is a not for profit company limited by guarantee.  
Hilmer Building (E10), Union Rd, UNSW, Kensington, NSW, 2052.

